Molecular Basis of Breast Tumor Heterogeneity

Advances in experimental medicine and biology, Год журнала: 2025, Номер unknown, С. 237 - 257

Опубликована: Янв. 1, 2025

Язык: Английский

---

What the clinician needs to know about laboratory analyses of circulating tumor DNA

Clinical Colorectal Cancer, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

---

Analytical Validation of the Labcorp Plasma Complete Test, a Cell-free DNA Comprehensive Genomic Profiling Tool for Precision Oncology

Journal of Molecular Diagnostics, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

---

Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis

The Oncologist, Год журнала: 2025, Номер 30(2)

Опубликована: Фев. 1, 2025

Abstract Background Predicting early treatment response in advanced non-small cell lung cancer (NSCLC) is challenging. Longitudinal monitoring of circulating tumor DNA (ctDNA) can track to treatments like immune checkpoint blockade (ICB) and correlate with outcomes. This meta-analysis evaluated whether ctDNA clearance or decrease associated improved survival across various settings NSCLC. Methods A systematic review MEDLINE, EMBASE, Cochrane databases (up April 2024) identified studies evaluating the impact kinetics on outcomes non-curative NSCLC settings. Pooled hazard ratios (HR) for progression-free (PFS) overall (OS) were calculated using a random effects model. Results We included 32 3047 patients receiving systemic therapies such as targeted therapy (TT), ICB, chemotherapy. Meta-analysis 31 showed that decrease/clearance was linked PFS (HR: 0.32 [0.26, 0.40], I² = 63%, P < .01). Subgroup analysis indicated strong benefits from 0.27 [0.20, 0.36]). Similar improvements seen undergoing 0.34) ICB 0.33). Analysis 25 revealed significant association between reduction better OS 0.31 [0.23, 0.42], 47%, findings consistent both TT 0.41) 0.32). Sensitivity demonstrated clearance/decrease consistently study designs methods. There no variation based subtypes, smoking status, sex. Conclusion Plasma diagnosed ICB.

Язык: Английский

---

Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium

Clinical and Translational Science, Год журнала: 2025, Номер 18(3)

Опубликована: Март 1, 2025

ABSTRACT The use of a liquid biopsy to assess molecular residual disease (MRD) solid tumors holds significant promise for improving outcomes patients with cancer. Liquid biopsies are minimally invasive approach the identification circulating tumor biomarkers through simple blood sample. Assays capable detecting MRD analysis DNA (ctDNA) rapidly evolving clinical study applications and therapeutic interventions. To address these opportunities, BLOODPAC—a multi‐disciplinary consortium representing stakeholders from public, industry, academia, regulatory agencies—formulated lexicon that provides shared framework clear definitions using an emphasis on ctDNA detection. terms in categorized under general MRD, testing methodologies, reporting results, acquisition timepoints, including examples current potential cases tests. overall goal is provide unified language approaches advance technologies, allow data aggregation strengthen future evidence, facilitate approvals, leading as early endpoint trials. We believe common set terminology methods can improve understanding appropriate testing, accelerate development, cancer patients.

Язык: Английский

---

Translating the multifaceted use of liquid biopsy to management of early disease in pancreatic adenocarcinoma

Frontiers in Oncology, Год журнала: 2025, Номер 15

Опубликована: Март 13, 2025

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality, primarily due to late stage at diagnosis. This review examines the multifaceted applications liquid biopsy and circulating tumor DNA (ctDNA) analysis in diagnosis management PDAC. We current literature on technological advancements such as next generation sequencing (NGS) digital droplet PCR (ddPCR) well multi-omics technologies, highlighting their potential for accurate molecular subtyping through ctDNA analysis. highlights significant role assessment behavior, disease subtyping, prediction monitoring treatment response, evaluation minimal residual disease. discuss implications integrating techniques into clinical practice its challenges limitations. By drawing insights from recent studies, this aims provide comprehensive overview how can enhance early strategies underscore need additional prospective studies trials validate feasibility accuracy order establish utility, with ultimate goal routine incorporation improve patient outcomes transform landscape

Язык: Английский

---

Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study

JCO Precision Oncology, Год журнала: 2025, Номер 9

Опубликована: Апрель 1, 2025

PURPOSE The utility of capturing heterogeneity by circulating tumor DNA (ctDNA) genotyping combined with tissue analysis or applying it in a sequential manner remains uncertain. METHODS We assessed the clinical value ctDNA using data from 2,187 patients advanced solid tumors enrolled SCRUM-Japan MONSTAR-SCREEN-1, nationwide cancer genome screening project, which examined longitudinally collected blood samples and (UMIN 000036749). RESULTS Among 667 both baseline results, 51 (7.6%) had actionable biomarkers identified exclusively through genotyping. most frequent targets genotype-matched therapy guided solely were immune checkpoint, estrogen receptor, poly(ADP-ribose) polymerase (PARP). Comparison objective response rates (ORRs) progression-free survival (PFS) between treated based on versus alone showed no significant difference, ORRs 34.0% 23.1% ( P = .54) median PFS 11.5 13.8 months (hazard ratio [HR], 1.4 [95% CI, 0.72 to 2.80]), respectively. 924 undergoing genotyping, detection increased 63.2% 72.5% following subsequent ctDNA. Targets for commonly included PARP, BRAF. ORR was 23.2% 26.7% .75), 5.2 and. 3.7 (HR, 1.5 0.79 2.80]) initial alone, CONCLUSION Combining analysis, followed assessments, effectively enhances identification biomarkers. This strategy facilitates clinically beneficial, genetically informed therapies, underscoring its precision oncology.

Язык: Английский

---

Identification of Driver Mutations and Risk Stratification in Lung Adenocarcinoma via Liquid Biopsy

Cancers, Год журнала: 2025, Номер 17(8), С. 1340 - 1340

Опубликована: Апрель 16, 2025

Background: Liquid biopsy using plasma cfDNA has been established as a tool for informing the management of advanced-stage NSCLC. However, its effectiveness in early lung cancer detection, including identification high-risk cases, remains to be determined. Methods: We analyzed and matched tumors from 117 stage I–IV adenocarcinoma cases compared variants identified across all stages Oncomine Precision Assay on GenexusTM next-generation sequencing platform. Results: Cancer-specific mutations were detected approximately 72% (84/117) (all stages), with detection rates increasing by stage. Concordance between tumor tissue also increased 0% (stage I), 19% II), 45% III), 75% IV). KRAS concordant 22% (6/27) II 46% (11/24) III cases. Clinically important EGFR showed concordance 11% (1/9) 80% (8/10) III/IV Actionable mutations, targetable FDA-approved drugs, (4/37) II, 27% (12/45) III, 55% (4/9) IV underscoring potential liquid therapeutic targets. Moreover, co-occurring varying actionability more frequently than tissues. Plasma clinically was mostly associated disease, suggesting presence these indication disease progression. Conclusions: holds promise identifying serves complementary diagnostic advanced stages, enhancing strategies.

Язык: Английский

---

RNA methylation: A new promising biomaker in cancer liquid biopsy

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Год журнала: 2025, Номер unknown, С. 189337 - 189337

Опубликована: Апрель 1, 2025

Язык: Английский

---

Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial

Annals of Oncology, Год журнала: 2024, Номер unknown

Опубликована: Авг. 1, 2024

Язык: Английский

---